The Japanese healthcare revolution

Something that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and visitors alike.

BMS' Opdivo misses target in aggressive brain cancer trial

It’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Squibb’s PR team have had to issue news of another trial disappointment from the misfiring c

Novartis' lung cancer drug edges closer to market after FDA ...

An investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year after the FDA agreed to expedite development and review in a tough to treat form

BI signs KRAS deal with India's Lupin, as pharma awaits key ...

Boehringer Ingelheim has signed a deal with India’s Lupin to develop and market a potential cancer drug targeting tumours driven by the KRAS mutation.

More to come from PARP drugs, says biotech CEO after strikin...

Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers.

AZ gets China nod for Tagrisso in first-line lung cancer